The authors concluded that IDO gene therapy reduced arthritis via the up-regulation of the Trp degradation pathway, thus increasing kynurenine concentrations, leading to increased CD4+ T cell apoptosis and diminished IL-17 production (16). The gene discussed is IDO1; the disease is Arthritis.